Recruiting

Prognostic Model of Hypertension

The aim of this study was to establish a registration and monitoring system for hypertension in Xinjiang from 2020 to 2030 to obtain real information about patient basic information, patient characteristics, diagnostic test patterns, treatment options, and hospitalization outcomes (including mortality). Treatment complications, hospitalization costs, and end-of-life events (death, major adverse cardiac events, mild adverse cardiovascular events) in patients with hypertension in Xinjiang; and scientific prevention…

ClinicalTrials.gov IDNCT06160921
PhaseNot Applicable
Enrollment50000
SponsorXinjiang Medical University
AgeNo minimum reported
SexALL
I'm interested View official listing

Conditions studied

Hypertension

About this study

The aim of this study was to establish a registration and monitoring system for hypertension in Xinjiang from 2020 to 2030 to obtain real information about patient basic information, patient characteristics, diagnostic test patterns, treatment options, and hospitalization outcomes (including mortality). Treatment complications, hospitalization costs, and end-of-life events (death, major adverse cardiac events, mild adverse cardiovascular events) in patients with hypertension in Xinjiang; and scientific prevention strategies aimed at effectively preventing the onset of hypertension; Guidelines in clinical practice recommend, analyze and develop effective treatment strategies to optimize management and outcomes for patients with hypertension; and create cost-effective assessment systems.

Interventions

Primary outcomes

Eligibility information

Inclusion Criteria: * A patient diagnosed with primary hypertension who was admitted to the First Affiliated Hospital of Xinjiang Medical University Exclusion Criteria: * Patients with secondary hypertension, patients with liver and kidney dysfunction, * patients with mental disorders, and patients who are unwilling to participate in this trial

Study locations

Before you participate: Varda Clinical is an independent discovery tool, not the study sponsor or a medical provider. Eligibility can only be determined by the official study team. Discuss potential risks and benefits with a qualified healthcare professional.

Source: ClinicalTrials.gov. Record last refreshed by Varda Clinical: 2026-09-29.